<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2020-19-1-43-50</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-924</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Популяционный иммунитет к кори в Республике Беларусь в условиях многолетней вакцинации</article-title><trans-title-group xml:lang="en"><trans-title>Population Immunity to Measles in the Republic of Belarus Following Long-Standing Vaccination</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самойлович</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Samoilovich</surname><given-names>E. О.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самойлович Елена Олеговна - доктор медицинских наук, профессор.</p><p>Ул. Фимлимонова,23, Минск, 220114. +375 17 320 88 99 (office), +375 29 348 05 36</p></bio><bio xml:lang="en"><p>Samoilovich Elena O. - Dr. Sci. (Med.).</p><p>Srt. Filimonova, 23, Minsk, 220114. +375 17 320 88 99 (office), +375 29 348 05 36</p></bio><email xlink:type="simple">esamoilovich@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семейко</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Semeiko</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Валерьевна Семейко - кандидат биологических наук, ведущий научный сотрудник лаборатории вакциноуправляемых инфекций.</p><p>Минск,  +375 17 325 70 97</p></bio><bio xml:lang="en"><p>Galina V. Semeiko - Cand. Sci. (Biol.), leading researcher, Laboratory of Vaccine-Controlled Infections.</p></bio><email xlink:type="simple">g-semeiko@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ермолович</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yermalovich</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марина Анатольевна Ермолович - кандидат медицинских наук, ведущий научный сотрудник лаборатории вакциноуправляемых инфекций.</p><p>Минск, +375 17 325 70 97</p></bio><bio xml:lang="en"><p>Marina A. Yermolovich - Cand. Sci. (Med.), leading researcher at the vaccine-controlled infections laboratory.</p></bio><email xlink:type="simple">yermalovich@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глинская</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Glinskaya</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Николаевна Глинская - кандидат медицинских наук, заместитель главного врача по эпидемиологии.</p></bio><bio xml:lang="en"><p>Irina N. Glinskaya - Cand. Sci. (Med.), deputy chief physician for epidemiology.</p></bio><email xlink:type="simple">irinaglinskaya@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Высоцкая</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vysotskaya</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вероника Станиславовна Высоцкая - заведующая отделением иммунопрофилактики отдела эпидемиологии.</p><p>Минск, + 375 17 375 99 83</p></bio><bio xml:lang="en"><p>Veronika S. Vysotskaya - head of the Department of Immunoprophylaxis of the Department of Epidemiology.</p></bio><email xlink:type="simple">zavimun@rcheph.by</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский научно-практический центр эпидемиологии и микробиологии</institution><country>Беларусь</country></aff><aff xml:lang="en"><institution>Republican Research &amp;Practical Center for Epidemiology &amp; Microbiology</institution><country>Belarus</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Республиканский центр гигиены, эпидемиологии и общественного здравоохранения</institution><country>Беларусь</country></aff><aff xml:lang="en"><institution>Republican Center for Hygiene, Epidemiology &amp; Public Health</institution><country>Belarus</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>03</month><year>2020</year></pub-date><volume>19</volume><issue>1</issue><fpage>43</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Самойлович Е.О., Семейко Г.В., Ермолович М.А., Глинская И.Н., Высоцкая В.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Самойлович Е.О., Семейко Г.В., Ермолович М.А., Глинская И.Н., Высоцкая В.С.</copyright-holder><copyright-holder xml:lang="en">Samoilovich E.О., Semeiko G.V., Yermalovich M.A., Glinskaya I.N., Vysotskaya V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/924">https://www.epidemvac.ru/jour/article/view/924</self-uri><abstract><sec><title>Актульность</title><p>Актульность. Несмотря на успехи, достигнутые в элиминации кори и краснухи в Европейском регионе, в настоящее время ситуация по кори ухудшилась - четыре страны региона утратили статус элиминировавших корь.</p><p>Цель - оценка популяционного иммунитета к кори в Республике Беларусь, определение его возрастных и региональных характеристик для идентификации групп повышенного риска распространения инфекции.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Представлены результаты выполненного в 2019 г. исследования по определению уровня IgG к вирусу кори у 2229 жителей Республики Беларусь в возрасте 2-75 лет в условиях многолетнего (с 1967 г. - одна прививка, с 1987 г. - две прививки) применения вакцинации. Антитела определяли с использованием иммуноферментной тест-системы Serion ELISA classic measles virus IgG производства Virion\Serion, Германия. Выявление антител в концентрации 150 мМЕ/мл и более расценивали как свидетельство защищенности от кори. Установлено, что уровень популяционного иммунитета к кори в Республике Беларусь в 2019 г. составил 84,6%, что ниже порогового уровня (90-95%), достаточного для предотвращения широкой трансмиссии вируса в случае его завоза. Уровень серопозитивных был наиболее высоким среди детей 2-5 лет (96,9%), а также среди взрослых 46 лет и старше (93,0% и более) и не достигал 90% во всех остальных возрастных группах. Наиболее восприимчивыми к кори являлись взрослые 31-40 лет (1979-1988 года рождения) - антитела в защитной концентрации были выявлены менее чем у 80% обследованных (31-35 лет - 78,9% и 36-40 лет -78,4%). Средняя концентрация антител у серопозитивных также различалась в возрастных группах населения. Высокая концентрация (более 1000 мМЕ/мл) отмечалась у детей 2-5 лет, а также у взрослых старше 40 лет. Среди последних концентрация антител повышалась с возрастом: 41-45 лет - 1069 мМЕ/мл, 46-55 лет - 1212 мМЕ/мл, 56-65 лет - 1582 мМЕ/мл, 66-75 -1849 мМЕ/мл. Среди лиц 6-35 лет она находилась в пределах 500-600 мМЕ/мл и была несколько выше среди лиц 36-40 лет (781 мМЕ/мл).</p></sec><sec><title>Выводы</title><p>Выводы. Для дальнейшего контроля инфекции, наряду с поддержанием высокого (97% и более) уровня рутинной иммунизации, необходимо обеспечить выявление и проведение подчищающей иммунизации не привитых лиц и лиц без данных о прививках.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. Despite the progress made in eliminating measles and rubella in the European Region, the measles situation has now worsened - four countries in the region have lost their status of eliminating measles.</p><p>Aims - to assess population immunity to measles in the Republic of Belarus, to determine its age and regional characteristics for identification of groups of higher risk of infection.</p></sec><sec><title>Results</title><p>Results. The results of evaluation of IgG antibodies to measles under the conditions of a long-term (since 1967 - singledose immunization schedule, since 1987 - two-dose) vaccination, carried out in 2019, in 2229 residents of the Republic of Belarus 2-75 years of age are presented. Antibodies were detected using Serion ELISA classic Measles Virus IgG, Virion\Serion, Germany. Antibodies concentration 150 mIU/ml or more was considered as evidence of protection against measles. It was found that the level of seroprevalence against measles in the Republic of Belarus is 84.6%, that is slightly lower than the threshold level (90-95%) sufficient to prevent wide transmission of the virus in case of its importation. Level of seroprevalence was the highest in children 2-5 years old (96.9%) and in adults 46 years of age and older (93.0% or more) and did not reach 90% in all other age groups. The most susceptible to measles were adults 31-40 years old (born 1979-1988) - antibodies in protective concentrations were detected in less than 80% of them (31-35 years old - 78.9% and 36-40 years old - 78,4%). The mean antibody concentration in seropositive individuals also varied in age groups. A high concentration of antibodies (more than 1000 mIU/ml) was observed in children 2-5 years old, as well as in adults over 40 years old. Among the latter, the concentration of antibodies increased with age: 41-45 years old - 1069 mIU/ ml, 46-55 years old -1212 mIU/ml, 56-65years old -1582 mIU/ml, 66-75 -1849 mIU/ml. Among people 6-35 years old it was 500600 mIU/ml and was slightly higher among persons 36-40 years old (781 mIU/ml).</p></sec><sec><title>Conclusions</title><p>Conclusions. For further control of infection, along with maintaining a high (97% or more) level of routine immunization, it is necessary to ensure mopping up immunization of unvaccinated individuals and those without immunization data.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>корь</kwd><kwd>сероэпидемиологическое исследование</kwd><kwd>популяционный иммунитет</kwd><kwd>IgG антитела</kwd></kwd-group><kwd-group xml:lang="en"><kwd>measles</kwd><kwd>seroepidemiological research</kwd><kwd>population immunity</kwd><kwd>IgG antibodies No conflict of interest to declare</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Европейское региональное бюро Всемирной организации здравоохранения. Эпидемиологическая справка ВОЗ. 2019. № 1. С. 1-10. Доступно на: http://www.euro.who.int/data/assets/pdf_file/0019/403156/EpiBrief_1_2019_RU.pdf?ua=1.</mixed-citation><mixed-citation xml:lang="en">World Health Organization Regional Office for Europe. WHO EpiBrief. 2019; (1): 1-9. Available at: http://www.euro.who.int/data/assets/pdf_file/0013/400252/EpiBrief_1_2019_EN.pdf?ua=1.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Европейское региональное бюро Всемирной организации здравоохранения. Восьмое совещание Европейской региональной комиссии по верификации элиминации кори и краснухи (РКВ), Варшава, Польша, 12-14 июня2019г. Доступно по: http://www.euro.who.int/_data/assets/pdf_file/0003/417900/RVC_Rus.pdf?ua=1. Ссылка активна 21 января 2020.</mixed-citation><mixed-citation xml:lang="en">World Health Organization Regional Office for Europe. 8 th Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC), Warsaw, Poland, 12-14 June 2019. Available at: http://www.euro.who.int/__data/assets/pdf_file/0019/413236/8th-RVC-Report.pdf?ua=1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Европейское региональное бюро Всемирной организации здравоохранения. Эпидемиологическая справка ВОЗ. 2019. № 2. С. 1-7. Доступно по: http://www.euro.who.intdata/assets/pdf_file/0019/410851/EpiBrief_2_2019_Russian.PDF?ua=1. Ссылка активна на 14 января 2020.</mixed-citation><mixed-citation xml:lang="en">World Health Organization Regional Office for Europe. WHO EpiBrief. 2019; (2): 1-7. Available at: http://www.euro.who.int/_data/assets/pdf_file/0017/410714/EpiBrief_2_2019_EN.p df.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Самойлович Е.О. Надзор за корью в Республике Беларусь; подготовка к верификации элиминации инфекции. //Медицинский журнал. 2014. № 2. С. 94-99. Доступно на: https://medmag.bsmu.by/category48/article2292/.</mixed-citation><mixed-citation xml:lang="en">Samoilovich EO. Measles surveillance in Belarus: background for verification of infection elimination. Medical Journal. 2014; (2): 94-9. Available at: https://medmag.bsmu.by/category48/article2292. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Самойлович Е. О., Семейко Г. В., Ермолович М. А., и др. Достижения в элиминации кори и краснухи в Республике Беларусь. //Эпидемиология и Вакцинопрофилактика. 2016. Т. 15, № 4. С. 94-99. https://doi.org/10.31631/2073-3046-2016-15-4-94-99.</mixed-citation><mixed-citation xml:lang="en">Samoilovich EO, Semeiko GV, Yermalovich MA, et al. Achievements in measles and rubella elimination in the Republic of Belarus. Epidemiology and Vaccinal Prevention. 2016; 15 (4): 94 -9 (In Russ.). https://doi.org/10.31631/2073-3046-2016-15-4-94-99.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: University press, 1992.</mixed-citation><mixed-citation xml:lang="en">Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: University press, 1992.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organaization Regional Office for Europe. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. Copenhagen, Denmark; 2013.</mixed-citation><mixed-citation xml:lang="en">World Health Organaization Regional Office for Europe. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. Copenhagen, Denmark. 2013:</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">P. 1-25. Доступно на: http://www.euro.who.int/data/assets/pdf_file/0011/236648/Guidance-on-conducting-serosurveys-in-support-of-measles-and-rubella-elimination-in-the-WHO-European-Region.pdf.</mixed-citation><mixed-citation xml:lang="en">Available at: http://www.euro.who.int/_data/assets/pdf_file/0011/236648/Guidance-on-conducting-serosurveys-in-support-of-measles-and-rubella-elimination-in-the-WHO-European-Region.pdf. Accessed: 20 Jan 2020.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Самойлович Е. О., Свирчевская Е. Ю., Ермолович М. А. и др. Популяционный иммунитет к кори в Республике Беларусь в 2011 г. В сб. науч. тр.: Современные проблемы инфекционной патологии человека. Минск: РНМБ; 2011. Вып. 4. С. 44-47. Доступно на: http://belriem.by/images/docs/sb2012.pdf.</mixed-citation><mixed-citation xml:lang="en">Samoilovich EO, Svirchevskaya EJu, Yermalovich MA et al. Herd immunity to measles in the Republic of Belarus, 2011. In: Sovremennye problemy infekcionnoj patologii cheloveka. Minsk: RSML; 2011. Issue 4:44-7(in Russ.). Available at:http://med.by/content/ellibsci/RNPCEIM/rnpceim_2011_4.pdf. Accessed: 20 Jan 2020.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lebo EJ, Kruszon-Moran DM, Marin M et al. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010. // Open Forum Infect Dis. 2015. Vol. 2, N 1. ofv006. doi: 10.1093/ofid/ofv006.</mixed-citation><mixed-citation xml:lang="en">Lebo EJ, Kruszon-Moran DM, Marin M et al. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010. Open Forum Infect Dis. 2015; 2 (1): ofv006. doi: 10.1093/ofid/ofv006.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Funk S, Knapp JK, Lebo E et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019; 17:180. dor.10.1186/s12916-019-1413-7</mixed-citation><mixed-citation xml:lang="en">Funk S, Knapp JK, Lebo E et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019; 17:180. doi:10.1186/ s12916-019-1413-7</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Коревые вакцины: документ по позиции ВОЗ - апрель 2017//Еженедельный эпидемиологический бюллетень 28 апреля 2017года. 2017. Т. 92, № 17. С. 205-228. Доступно на: https://www.who.int/immunization/policy/position_papers/PP_measles_apr_2017_RU.pdf?ua=1.</mixed-citation><mixed-citation xml:lang="en">Measles vaccines: WHO position paper - April 2017. Weekly Epidemiol Record. 28 Apr 2017; 92 (17):205 -28. Available at: http://apps.who.int/iris/bitstream/10665/255149/1/WER9217.pdf?ua=128. Available at: http://apps.who.int/iris/bitstream/10665/255149/1/WER9217.pdf?ua=1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">McLean HQ, Fiebelkorn AP, Temte JL et al. Centers for Disease Control and Prevention. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2013. Vol. 62, RR-04. P. 1 -34. Erratum in: MMWR Recomm. Rep. 2015. Vol. 64, N 9. P. 259.</mixed-citation><mixed-citation xml:lang="en">McLean HQ, Fiebelkorn AP, Temte JL et al. Centers for Disease Control and Prevention. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2013; 62, RR-04: 1 -34. Erratum in: MMWR Recomm. Rep. 2015; 64 (9): 259.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Davidkin I, Jokinen S, Broman M et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008. Vol. 197, N 7. P. 950-956. doi: 10.1086/528993.</mixed-citation><mixed-citation xml:lang="en">Davidkin I, Jokinen S, Broman M et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008; 197 (7): 950-956. doi:10.1086/528993.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dine MS, Hutchins SS, Thomas A et al. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J. Infect. Dis. 2004. Vol. 189, Suppl. 1. P. S123-S130.</mixed-citation><mixed-citation xml:lang="en">Dine MS, Hutchins SS, Thomas A et al. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J. Infect. Dis. 2004; 189 (Suppl. 1): S123-S130.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Seagle EE, Bednarczyk RA, Hill T et al. Measles, mumps and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine. 2018. Vol. 36, N 6. P. 818-826. doi: 10.1016/j.vaccine.2017.12.075.</mixed-citation><mixed-citation xml:lang="en">Seagle EE, Bednarczyk RA, Hill T et al. Measles, mumps and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine. 2018; 36 (6): 818-826. doi: 10.1016/j.vaccine.2017.12.075.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Gidding HF, Quinn HE, Hueston L et al. Declining measles antibodies in the era of elimination: Australia's experience. Vaccine. 2018. Vol. 36, N 4. P. 507-513. doi: 10.1016/j.vaccine.2017.12.002.</mixed-citation><mixed-citation xml:lang="en">Gidding HF, Quinn HE, Hueston L et al. Declining measles antibodies in the era of elimination: Australia's experience. Vaccine. 2018; 36 (4): 507-513. doi: 10.1016/j.vaccine.2017.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dimech W, Mulders MN A 16-year review of seroprevalence studies on measles and rubella. Vaccine. 2016. Vol. 34, N 35:4110-4118. doi: 10.1016/j.vaccine.2016.06.002.</mixed-citation><mixed-citation xml:lang="en">Dimech W, Mulders MN A 16-year review of seroprevalence studies on measles and rubella. Vaccine. 2016; 34 (35): 4110-4118. doi: 10.1016/j.vaccine.2016.06.002.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. The Immunological Basis for Immunization Series. Module 7: Measles - Update 2009. Geneva, CH: WHO Press, 2009. Доступно на: https://apps.who.int/iris/bitstream/handle/10665/44038/9789241597555_eng.pdf?sequence=1.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. The Immunological Basis for Immunization Series. Module 7: Measles - Update 2009. Geneva, CH: WHO Press, 2009. Available at: https://apps.who.int/iris/bitstream/handle/10665/44038/9789241597555_eng.pdf?sequence=1</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tischer A, Gassner M, Richard JL et al. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralization test. J. Clin. Virol. 2007. Vol. 38, N 3. P. 204-209.</mixed-citation><mixed-citation xml:lang="en">Tischer A, Gassner M, Richard JL et al. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralization test. J. Clin. Virol. 2007; 38 (3): 204-209.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine. 2008. Vol.26, N50. P. 6392-6397. doi: 10.1016/j.vaccine.2008.08.074.</mixed-citation><mixed-citation xml:lang="en">Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine. 2008; 26 (50): 6392-6397. doi: 10.1016/j.vaccine.2008.08.074.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Свирчевская Е. Ю. Эпидемиологический и вирусологический мониторинг кори на этапе ее элиминации в Республике Беларусь: Дисс. ... канд. биол. наук. Минск; 2008.</mixed-citation><mixed-citation xml:lang="en">Svirchevskaja EJu. Jepidemiologicheskij i virusologicheskij monitoring kori na jetape ee jeliminacii v Respublike Belarus [dissertation]. Minsk;2008.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bolotin S, Severini A, Hatchette T et al. Assessment of population immunity to measles in Ontario, Canada: a Canadian Immune Research Network (CIRN) study. Human Vaccines &amp; Immunization. 2019. https://doi.org/10.1080/21645515.2019.1619402</mixed-citation><mixed-citation xml:lang="en">Bolotin S, Severini A, Hatchette T et al. Assessment of population immunity to measles in Ontario, Canada: a Canadian Immune Research Network (CIRN) study. Human Vaccines &amp; Immunization. 2019. https://doi.org/10.1080/21645515.2019.1619402</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
